Antiretroviral compounds have been predominantly studied in human immunodeficiency virus type 1 (HIV-1) subtype B, but only ~10% of infections worldwide are caused by this subtype. The analysis of the impact of different HIV subtypes on treatment outcome is important
The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resista...
Background. To analyze the time trends of the viral subtype distributions according to gender, risk ...
Background: We aimed to compare rates of virologic response and CD4 changes after combination ant...
(See the Editorial Commentary by Gatell, on pages 1153–5.) Background. Antiretroviral compounds have...
Patients infected with HIV type 1 non-B subtypes had a decreased probability for a virological failu...
BACKGROUND: Antiretroviral compounds have been predominantly studied in human immunodeficiency virus...
(See the article by Scherrer et al, on pages 1143–52.) About 2 years ago, in a past issue of Clinica...
Currently, 24 active antiretroviral agents are available for use in the United States. These agents ...
Highly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and mor...
Introduction HIV is a highly diverse virus with significant genetic variability which may confer bio...
IntroductionHIV is a highly diverse virus with significant genetic variability which may confer biol...
Although human immunode®ciency virus type 1 (HIV-1) infection in the United States has predominantly...
Despite advances in antiretroviral therapy that have revolutionized HIV disease management, effectiv...
Despite the fact that over 90% of HIV-1 infected people worldwide harbor non‑subtype B variants of H...
There are 31 million adults living with HIV-1 non-B subtypes globally, and about 10 million are on a...
The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resista...
Background. To analyze the time trends of the viral subtype distributions according to gender, risk ...
Background: We aimed to compare rates of virologic response and CD4 changes after combination ant...
(See the Editorial Commentary by Gatell, on pages 1153–5.) Background. Antiretroviral compounds have...
Patients infected with HIV type 1 non-B subtypes had a decreased probability for a virological failu...
BACKGROUND: Antiretroviral compounds have been predominantly studied in human immunodeficiency virus...
(See the article by Scherrer et al, on pages 1143–52.) About 2 years ago, in a past issue of Clinica...
Currently, 24 active antiretroviral agents are available for use in the United States. These agents ...
Highly active antiretroviral therapy (HAART) has led to a reduction in HIV-related mortality and mor...
Introduction HIV is a highly diverse virus with significant genetic variability which may confer bio...
IntroductionHIV is a highly diverse virus with significant genetic variability which may confer biol...
Although human immunode®ciency virus type 1 (HIV-1) infection in the United States has predominantly...
Despite advances in antiretroviral therapy that have revolutionized HIV disease management, effectiv...
Despite the fact that over 90% of HIV-1 infected people worldwide harbor non‑subtype B variants of H...
There are 31 million adults living with HIV-1 non-B subtypes globally, and about 10 million are on a...
The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resista...
Background. To analyze the time trends of the viral subtype distributions according to gender, risk ...
Background: We aimed to compare rates of virologic response and CD4 changes after combination ant...